Citation Tools

Download PDFPDF

Original research
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Download to a citation manager

Cite this article as:
Shah AN, Flaum L, Helenowski I, et al
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer